Every biologic drug leaves manufacturing with quality data. But once it moves through real-world supply chains and into patients’ homes, that quality becomes invisible.
Beyond Diagnostics is building LUMIQ, a point-of-care medication quality platform that verifies biologic drugs still work in real-world use, starting with insulin, because heat, handling and storage can compromise insulin quality long before patients can detect it.
And as more temperature-sensitive biologics, from GLP-1s to oncology drugs, move into home care, medication quality becomes one of the last unmeasured risks in therapy. LUMIQ creates a new category: real-world medication quality verification for biologics.
We combine rapid strip-based testing, smartphone-based optical readout and AI-supported calibration.
No news
15.04.2026
11.02.2026
Winner of ATTD Ignite Startup Competition
01.02.2026
First functional prototype for insulin activity testing developed
01.08.2025
Stage Up Award Winner
01.07.2025
Biological activity assay validated (in vitro)
No Jobs
No videos and documents
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Website:
www.beyond-diagnostics.com
Headquarter:
Bern
Foundation Date:
February 2026
Technology:
Sectors: